Q3 2024 Theravance Biopharma Inc Earnings Call Transcript

Nov 12, 2024 / 10:00PM GMT

Release Date Price: $8.91 (-1.87%)

Transcript 10-Q8-K

Key Points

Positve

Theravance Biopharma Inc (TBPH) reported a 7% year-over-year growth in net sales, reaching an all-time high of $62.2 million.
The company made solid progress on its pivotal Cypress study for Ampel Oxetin, remaining on target to achieve updated timelines.
GSK delivered strong Trilogy sales, reaching $789 million for the quarter, positioning Theravance Biopharma Inc (TBPH) to achieve a $50 million sales milestone.
The board of directors has separated the roles of CEO and Chair, with Susanna Gray elected as Chair, enhancing governance practices.
Theravance Biopharma Inc (TBPH) formed a strategic review committee to explore alternatives to unlock value, aligning with shareholder interests.

Negative

The company faces pricing headwinds due to channel mix and one-time charges impacting quarterly pricing.
There is a lag in the impact of pricing initiatives, with improvements expected to be seen in early 2025.
Theravance Biopharma Inc (TBPH) incurred a $1.6 million non-cash impairment charge due to the write-down of operating lease assets.
The company expects higher non-cash tax charges in Q4 due to better-than-expected results and other non-cash charges.
Despite progress, the company acknowledges significant unmet needs in the market, particularly in the treatment of symptomatic NOH in MSA patients.

Operator

Ladies and gentlemen. Good afternoon. I'd like to welcome everyone to the Fair Advance Bio former third quarter, 2024 conference call. During the presentation, all participants will be in a listen-only mode, a question and answer session will follow the company's formal formal remarks to ask a question. Press star, press the star key followed by the digit one digit one on your phone. Again, that's star 11 to ask the question. If listening via webcast, please mute your audio on your webcast advice before asking a question over the phone. I'll repeat the instructions after manvi completes their prepared remarks. Also, today's conference call is being recorded and now I'd like to turn the conference over to Rick Whittingham, Chief Executive Officer. Please go ahead, sir.

Rick Winningham

Theravance Biopharma Inc - Chairman of the Board, Chief Executive Officer

Good afternoon and welcome to the Advance by Cors third quarter, 2024 earnings results conference call. I encourage you to review our forward-looking statements. Disclaimer on slide 2 which covers certain

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.